What Type 1 Diabetes Teaches All of Us About Insulin, Metabolic Health, and Cardiovascular Risk

Type 1 diabetes is often thought of as a disease that affects a small population, approximately one in 300 people, and has little relevance to the health of everyone else. That assumption is wrong in a way that I think has profound implications for how we all think about metabolic health, cardiovascular risk, and the role of insulin in long-term wellbeing.

What the study of type 1 diabetes reveals is something that gets far too little attention in conventional medicine: it is not just elevated blood glucose that drives disease. It is elevated insulin. And the consequences of chronic hyperinsulinemia, including accelerated cardiovascular aging and weight gain, are not exclusive to diabetics. They are playing out across the general population right now, driven largely by the same Standard American Diet that challenges people with type 1 diabetes every day.

Let me walk you through what this disease teaches us, and why the lessons apply to every patient I work with.

1. What Type 1 Diabetes Actually Is

Type 1 diabetes is an autoimmune disease. The immune system, through a process involving both T cells and B cells, progressively destroys the beta cells of the pancreas, the cells responsible for producing insulin. Without beta cells, the body cannot produce insulin at all. A person with type 1 diabetes must inject exogenous insulin to survive. Without it, they develop diabetic ketoacidosis and die.

Prior to the discovery of insulin in 1921 by Frederick Banting and Charles Best, a diagnosis of type 1 diabetes was a death sentence. Children who developed the disease died within weeks to months. The discovery of insulin is arguably one of the most important moments in the history of medicine. It transformed a uniformly fatal disease into a manageable, chronic condition.

But manageable is not the same as solved. The challenge of type 1 diabetes is not simply that the body cannot produce insulin. It is that replacing insulin exogenously with precision is extraordinarily difficult. Blood glucose is affected not just by food but by sleep quality, stress, exercise, the ratio of macronutrients in a meal, the timing of that meal, and dozens of other variables. There is no perfect formula. Managing it well requires constant vigilance, significant cognitive load, and in many cases produces significant psychological burden alongside the physical one.

2. The Cognitive and Emotional Toll

One of the aspects of type 1 diabetes that conventional medicine has consistently underappreciated is its psychological impact. Approximately 40 to 50 percent of people living with type 1 diabetes experience depression or anxiety. This is not incidental. It is directly connected to the relentless cognitive burden of managing a disease that never takes a day off.

The cognitive load of diabetes, the constant monitoring of blood glucose, the calculation of insulin doses, the fear of hypoglycemia, the anxiety of unexpected spikes, is experienced by patients on a scale of 1 to 10. For teenagers managing a high-carbohydrate diet, the average score approaches 7 or 8. They are not being non-compliant, as they are often told. They are exhausted by a system that is working against them.

This matters beyond the diabetes population because it illustrates a broader principle. When we give patients a protocol that generates constant volatility, constant fear, and constant failure, and then blame them for not following it perfectly, we have failed them. The most compassionate and effective approach starts with reducing the volatility itself, not with demanding more precision from already overwhelmed patients.

3. The DCCT: What Tight Blood Glucose Control Actually Proved

The Diabetes Control and Complications Trial, published in 1993, was one of the landmark studies in endocrinology. It set out to answer whether tight blood glucose control, keeping hemoglobin A1c near normal, would reduce the devastating microvascular complications of type 1 diabetes: blindness, kidney failure, and amputations.

The answer was an unambiguous yes. Tighter blood glucose control dramatically reduced microvascular complications. The trial was stopped after seven years, two years earlier than planned, because the benefit in the tightly controlled group was so significant that it was considered unethical to continue withholding better treatment from the control group.

The thirty-year follow-up to the DCCT produced an even more remarkable finding. The group that had received intensive blood glucose control for just those seven years had significantly less cardiovascular disease and death than the group that had received conventional treatment, even thirty years later. Seven years of tight control, three decades earlier, continued to protect the heart and vasculature. This finding, which researchers call metabolic memory or legacy effect, tells us something profound: the metabolic environment your cells are exposed to early leaves a lasting biological imprint.

But the DCCT also revealed a critical problem. The way tight control was achieved was by using more insulin. And more insulin came with two significant side effects: more hypoglycemic events and significant weight gain. This observation is at the heart of the most important lesson type 1 diabetes has to teach the rest of us.

4. The Insulin Problem: Why More Is Not Always Better

Here is the central insight from the type 1 diabetes literature that I want every patient to understand.

In type 1 diabetes, you can observe something that is impossible to observe in the general population: the exact amount of insulin going into a person and its direct effect on their weight and cardiovascular health. What this natural experiment has consistently shown is that patients on higher doses of insulin to control their blood glucose gain more weight and have worse cardiovascular outcomes than patients who control their blood glucose with lower doses.

This tells us that insulin itself, independent of blood glucose, is driving weight gain and cardiovascular risk. And when you look at the comparison between two types of diabetes treatments, those that lower blood glucose by increasing insulin versus those that lower blood glucose without raising insulin, the data confirms it. Both approaches produce equivalent microvascular outcomes. But the higher-insulin approaches produce significantly more macrovascular disease, meaning more coronary artery disease, cerebrovascular disease, and peripheral vascular disease.

The SGLT-2 inhibitors, a newer class of drugs that lower blood glucose by directing glucose into the urine rather than by increasing insulin, have shown a 40 percent reduction in cardiovascular disease. Not because they lowered blood glucose more than other drugs. Because they lowered circulating insulin.

The implication for the broader population is direct. Chronic hyperinsulinemia, driven by a high-carbohydrate diet that requires the pancreas to produce large amounts of insulin to manage the glucose load, is likely contributing to the cardiovascular epidemic we are living through. The Standard American Diet is not just causing weight gain. It is driving the insulin levels that drive that weight gain, and those insulin levels are independently driving cardiovascular risk.

This is why at RMRM, we assess fasting insulin, HOMA-IR, and insulin dynamics alongside blood glucose as part of any comprehensive metabolic evaluation. Managing blood glucose to a normal range while leaving insulin elevated is not adequate metabolic health management. It is incomplete care.

5. The Law of Small Numbers: The Most Practical Lesson

One of the most elegant and practical frameworks in diabetes management comes from Dr. Richard Bernstein, a physician with type 1 diabetes who has been his own primary research subject for decades.

His core insight is called the Law of Small Numbers. If you consume large amounts of carbohydrates, you need large amounts of insulin to manage them. Large amounts of insulin create large opportunities for error, large swings in blood glucose, and large consequences when the dosing is not perfect. If you consume small amounts of carbohydrates, you need small amounts of insulin, and the margin for error is dramatically smaller.

This principle extends directly to the non-diabetic population. The person eating a high-carbohydrate diet is not just consuming more glucose. They are requiring their pancreas to produce large amounts of insulin repeatedly throughout the day. Over years and decades, that chronic insulin demand drives insulin resistance, weight gain, visceral fat accumulation, and eventually the metabolic dysfunction that underlies cardiovascular disease, metabolic syndrome, and type 2 diabetes.

Reducing carbohydrate intake, particularly refined carbohydrates and sugars, is not just a weight loss strategy. It is a direct reduction in insulin demand. And reducing insulin demand is one of the most powerful metabolic interventions available to the general population.

6. Exercise as Metabolic Medicine

Exercise has a unique and powerful effect on glucose metabolism that is particularly valuable for people with type 1 diabetes but equally relevant for everyone else. The mechanism involves AMPK, an enzyme that senses the energy status of the cell and, when activated by exercise, signals GLUT4 glucose transporters to move to the muscle cell surface through an entirely insulin-independent pathway.

This means that exercise allows glucose to enter muscle cells without requiring insulin. For a person with type 1 diabetes, this can dramatically reduce their total insulin requirement. For the general population, it improves insulin sensitivity at a cellular level, making every unit of insulin more effective and reducing the total amount the pancreas needs to produce.

The most insulin-efficient patients I have encountered are those who combine low carbohydrate eating with consistent daily movement. The combination of reduced glucose load and enhanced insulin-independent glucose uptake creates a metabolic environment that is profoundly protective. This is not theoretical. It is observable in the metabolic markers I track for every patient.

Regular aerobic exercise, particularly long duration steady-state activity, appears to have the most dramatic effect on total insulin reduction. Resistance training adds additional benefits through increased muscle mass, which is itself a major site of glucose disposal. Both are important components of a comprehensive metabolic health strategy.

7. What Continuous Glucose Monitoring Reveals

One of the most transformative tools in metabolic medicine over the past decade is the continuous glucose monitor, or CGM. Originally developed for people with diabetes, CGMs provide real-time blood glucose data throughout the day and night, revealing patterns that are impossible to detect with the occasional fasting glucose measurement.

For people with type 1 diabetes, the CGM has been genuinely life-changing in terms of identifying the sources of blood glucose variability and enabling more precise management. But the insights that CGM data provides are not limited to diabetics.

Many non-diabetic individuals are surprised to discover that their blood glucose spikes dramatically after certain foods, or that their glucose variability is far higher than the occasional fasting glucose measurement would suggest. Some foods that are not conventionally considered high-glycemic produce significant glucose excursions in certain individuals. Stress, poor sleep, and sedentary periods all elevate glucose in ways that accumulate over time.

Frequently Asked Questions By Patients

Patient Success Stories

These patient success stories reflect our commitment to treating the root biological causes of knee pain, rather than just masking symptoms. Our mission is to help you restore function, stay active, and age stronger, so you can move better and live better every day.